Cognitive assessment in the Accelerating Medicines Partnership® Schizophrenia Program: harmonization priorities and strategies in a diverse international sample.
Allott K., Yassin W., Alameda L., Billah T., Borders O., Buccilli K., Carrión RE., Castillo-Passi RI., Cho KIK., Chin K., Coleman MJ., Colton B-L., Corral S., Dwyer D., Gundersen KB., Gur RC., Hoftman GD., Jacobs GR., Kelly S., Lewandowski KE., Marcy PJ., Matneja P., McLaughlin D., Nunez AR., Parsa S., Penzel N., Ray S., Reinen JM., Ruparel K., Sand MS., Santorelli G., Seitz-Holland J., Spark J., Tamayo Z., Thompson A., Tod S., Wannan CMJ., Wickham A., Wood SJ., Zoupou E., Addington J., Anticevic A., Arango C., Breitborde NJK., Broome MR., Cadenhead KS., Calkins ME., Chen EYH., Choi J., Conus P., Corcoran CM., Cornblatt BA., Ellman LM., Fusar-Poli P., Gaspar PA., Gerber C., Glenthøj LB., Horton LE., Hui CLM., Kambeitz J., Kambeitz-Ilankovic L., Keshavan M., Kim S-W., Koutsouleris N., Kwon JS., Langbein K., Mamah D., Diaz-Caneja CM., Mathalon DH., Mittal VA., Nordentoft M., Pearlson GD., Perkins DO., Perez J., Powers AR., Rogers J., Sabb FW., Schiffman J., Shah JL., Silverstein SM., Smesny S., Strauss GP., Thompson JL., Upthegrove R., Verma SK., Wang J., Wolf DH., Pasternak O., Bouix S., McGorry PD., Kane JM., Kahn RS., Bearden CE., Shenton ME., Woods SW., Nelson B., Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ) None., Stone WS.
Cognitive impairment occurs at higher rates in individuals at clinical high risk (CHR) for psychosis relative to healthy peers, and it contributes unique variance to multivariate prediction models of transition to psychosis. Such impairment is considered a core biomarker of schizophrenia. Thus, cognition is a key domain measured in the Accelerating Medicines Partnership® program for Schizophrenia (AMP SCZ initiative). The aim of this paper is to describe the rationale, processes, considerations, and final harmonization of the cognitive battery used in AMP SCZ across the two data collection networks. This battery comprises tests of general intellect and specific cognitive domains. We estimate premorbid intelligence at baseline and measure current intelligence at baseline and 2 years. Eight tests from the Penn Computerized Neurocognitive Battery (PennCNB), which measure verbal learning and memory, sensorimotor ability, attention, emotion recognition, working memory, processing speed, verbal memory, visual memory, and motor speed are administered repeatedly at baseline, and four follow-up timepoints over 2 years.